Plain language summary of the INCREASE study: inhaled treprostinil (Tyvaso) for the treatment of pulmonary hypertension due to interstitial lung disease

被引：2
|
作者：
West, Natalie [1 ,2 ]
Smoot, Karen [2 ]
Patzlaff, Natalie [1 ]
Miceli, Melissa [1 ]
Waxman, Aaron [3 ]
机构：
[1] United Therapeut Corp, 1040 Spring St, Silver Spring, MA 20910 USA
[2] Pulm Fibrosis Fdn, Chicago, IL 60611 USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
FUTURE CARDIOLOGY | 2023年 / 19卷 / 05期
关键词：
interstitial lung disease; lay summary; plain language summary; pulmonary hypertension; treprostinil;
D O I：
10.2217/fca-2022-0108
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A total of 326 participants took part in the study. Half the participants took inhaled treprostinil and the other half took placebo. After 16 weeks, the INCREASE study showed that participants with PH-ILD who took inhaled treprostinil could walk around 31 meters (102 feet) further than the participants who took placebo. Participants taking inhaled treprostinil also had a decrease in NT-proBNP, which is a protein found in the blood. Lower NT-proBNP levels suggest that the heart is functioning better compared with higher levels. Participants taking inhaled treprostinil showed a decrease of NT-proBNP of 15% compared to a 46% increase in participants taking placebo. More participants taking placebo had worsening of their PH-ILD (33%) compared to participants taking inhaled treprostinil (& SIM;23%). The most common side effects reported in the study were cough, headache, and shortness of breath.
引用
收藏
页码：229 / 239
页数：11
相关论文
共 50 条
  • [31] Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
    Nathan, Steven D.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (03) : 238 - 246
  • [32] Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment
    Behr, Juergen
    Nathan, Steven D.
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2021, 27 (05) : 396 - 404
  • [33] Pulmonary hypertension due to unclassified interstitial lung disease in a Pembroke Welsh corgi
    Morita, Tomoya
    Nakamura, Kensuke
    Osuga, Tatsuyuki
    Kobayashi, Atsushi
    Ichii, Osamu
    Yabuki, Akira
    Takiguchi, Mitsuyoshi
    [J]. JOURNAL OF VETERINARY MEDICAL SCIENCE, 2018, 80 (06): : 939 - 944
  • [34] Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease
    Mittoo, Shikha
    Jacob, Thomas
    Craig, Andrea
    Bshouty, Zoheir
    [J]. CANADIAN RESPIRATORY JOURNAL, 2010, 17 (06) : 282 - 286
  • [35] Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing
    Johnson, Shelsey W.
    Finlay, Lauren
    Mathai, Stephen C.
    Goldstein, Ronald H.
    Maron, Bradley A.
    [J]. PULMONARY CIRCULATION, 2022, 12 (03)
  • [36] Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life
    DuBrock, Hilary M.
    Nathan, Steven D.
    Reeve, Bryce B.
    Kolaitis, Nicholas A.
    Mathai, Stephen C.
    Classi, Peter M.
    Nelsen, Andrew C.
    Olayinka-Amao, Bimpe
    Norcross, Lindsey N.
    Martin, Susan A.
    [J]. PULMONARY CIRCULATION, 2021, 11 (02)
  • [37] Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease
    Chauvelot, Louis
    Gamondes, Delphine
    Berthiller, Julien
    Nieves, Ana
    Renard, Sebastien
    Catella-Chatron, Judith
    Ahmad, Kais
    Bertoletti, Laurent
    Camara, Boubou
    Gomez, Emmanuel
    Launay, David
    Montani, David
    Mornex, Jean-Francois
    Prevot, Gregoire
    Sanchez, Olivier
    Schott, Anne-Marie
    Subtil, Fabien
    Traclet, Julie
    Turquier, Segolene
    Zeghmar, Sabrina
    Habib, Gilbert
    Reynaud-Gaubert, Martine
    Humbert, Marc
    Cottin, Vincent
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 (02) : 295 - 304
  • [38] Can subcutaneous treprostinil be an alternative for treating pulmonary hypertension in patients with systemic sclerosis-related interstitial lung disease?
    Duarte, A. C.
    Alegria, S.
    Vinagre, F.
    Ferreira, F.
    Cordeiro, A.
    [J]. ARP RHEUMATOLOGY, 2024, 3 (02): : 162 - 164
  • [39] Inhaled nitric oxide in patients with pulmonary hypertension due to valvular heart disease and chronic lung disease
    Sakane, M
    Ishimitsu, T
    Ninomiya, H
    Ohtsu, I
    Saito, T
    Yamaguchi, I
    Hasegawa, S
    Sugishita, Y
    [J]. JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1998, 62 (12): : 877 - 882
  • [40] Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
    Richeldi, Luca
    Azuma, Arata
    Cottin, Vincent
    Hesslinger, Christian
    Stowasser, Susanne
    Valenzuela, Claudia
    Wijsenbeek, Marlies S.
    Zoz, Donald F.
    Voss, Florian
    Maher, Toby M.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022,
12345